Nektar Therapeutics
Delayed Nasdaq - 07/20 10:00:00 pm
48.73USD
-0.71%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Sales3081 181
EBITDA-28,9694
Operating profit (EBIT)-43,7692
Pre-Tax Profit (EBT)--
Net income-96,7669
EPS ( $ )-0,623,79
Dividend per Share ( $ )--
Yield--
Announcement Date03/01/2018
09:40pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 20172018
Debt--
Finance50,9469
Operating income (EBITDA)-28,9694
Leverage
(Debt/EBITDA)
--
Capital Expenditure9,686,75
Book Value Per Share (BVPS)0,55 $9,58 $
Cash Flow per Share-0,52 $4,00 $
Announcement Date03/01/2018
09:40pm
-
Balance Sheet Analysis
Financial Ratios
Size 2018e 2019e
Capitalization 10 079 M$ -
Entreprise Value (EV) 9 610 M$ 10 079 M$
Valuation 2018e 2019e
P/E ratio (Price / EPS) 15,4x
Capitalization / Revenue 8,53x 34,1x
EV / Revenue 8,13x 34,1x
EV / EBITDA 13,9x -101x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 6,10x 52,6x
Profitability 2018e 2019e
Operating Margin (EBIT / Sales) 58,6% -78,7%
operating Leverage (Delta EBIT / Delta Sales) 5,94x -1,78x
Net Margin (Net Profit / Revenue) 56,7% -84,8%
ROA (Net Profit / Asset) 43,3% 9,45%
ROE (Net Profit / Equities) 58,3% 10,2%
Rate of Dividend - -
Balance Sheet Analysis 2018e 2019e
CAPEX / CA   0,57% 4,27%
Cash Flow / Sales 58,4% -
Capital Intensity (Assets / Sales) 1,31x -8,98x
Financial Leverage (Net Debt / EBITDA) -0,68x -
Price Earning Ratio
BNA & Dividende